-transparent.png){kind=logo}
Serial assessments of some blood coagulation factors, antithrombin III (AT III), and complement were made in 18 patients with meningococcal (mgc) infection. All patients displayed laboratory evidence of activation of the blood clotting system. Two patients showed clinical signs of disseminated intravascular coagulation. Only AT III differed significantly between patients with and without complications. There was no correlation between changes in blood clotting, activation of the complement system and the course or duration of the disease. These results do not enable one t identify patients who need specific prophylactic therapy. Controlled clinical trials, including administration of heparin, dextran, aprotinin, and others, are still required to ensure optimal treatment in fulminant mgc infections.
B Laursen, and
V Faber, and
A Brock, and
J Gormsen, and
H Sørensen
January 1977,
Folia haematologica (Leipzig, Germany : 1928),
B Laursen, and
V Faber, and
A Brock, and
J Gormsen, and
H Sørensen
April 1980,
American journal of clinical pathology,
B Laursen, and
V Faber, and
A Brock, and
J Gormsen, and
H Sørensen
April 1978,
Lancet (London, England),
B Laursen, and
V Faber, and
A Brock, and
J Gormsen, and
H Sørensen
June 1978,
Lancet (London, England),
B Laursen, and
V Faber, and
A Brock, and
J Gormsen, and
H Sørensen
January 1983,
Nephron,
B Laursen, and
V Faber, and
A Brock, and
J Gormsen, and
H Sørensen
May 1989,
Circulatory shock,
B Laursen, and
V Faber, and
A Brock, and
J Gormsen, and
H Sørensen
February 1997,
Ugeskrift for laeger,
B Laursen, and
V Faber, and
A Brock, and
J Gormsen, and
H Sørensen
June 1982,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
B Laursen, and
V Faber, and
A Brock, and
J Gormsen, and
H Sørensen
June 1988,
Circulatory shock,
B Laursen, and
V Faber, and
A Brock, and
J Gormsen, and
H Sørensen
January 1981,
Thrombosis research,
